PSMA salivary gland toxicity: Langbein and colleagues look at xerostomia and related side effects of radiolabeled prostate-specific membrane antigen therapies and at the potential for avoiding, mitigating, or reversing these toxicities.
Page 1172
The immunoimaging toolbox: Mayer and Gambhir provide a comprehensive overview of current state-of-the-art immunoimaging, with a focus on imaging strategies and their applications in immunotherapy.
Page 1174
Controversies in radioiodine use: Pryma offers perspective on the challenges of over- and undertreatment with 131I in differentiated thyroid cancer and previews 2 related articles in this issue of JNM.
Page 1184
Thyroid cancer management: Tuttle examines 3 issues in thyroid cancer management: the option of thyroid lobectomy as initial therapy, preoperative neck imaging to optimize initial surgery, and use of 131I for remnant ablation, adjuvant treatment, or known persistent/recurrent disease.
Page 1187
In favor of radioiodine therapy: Schmidt and colleagues review differing opinions about 131I therapy in differentiated thyroid carcinoma and look at research and consensus guidelines that should be considered in treatment decisions for low- and intermediate-risk patients.
Page 1195
Photoacoustic molecular imaging: Yu and colleagues describe the current state of the art in photoacoustic molecular probes, recent translational efforts, and critical barriers to clinical translation of this novel technology.
Page 1202
18F-AlF–labeled biomolecule conjugates: Kumar surveys the development of 18F-AlF labeling as a novel, fast, simple, and inexpensive procedure and points to the need for target-specific biomolecules with demonstrated long-term in vitro and in vivo stability.
Page 1208
18F-FES PET/CT: Kurland and Oesterreich review the role of 18F-fluoroestradiol PET/CT in selecting and managing patients with metastatic breast cancer and in developing new therapies and call for more specific definitions of estrogen receptor heterogeneity.
Page 1210
Heterogeneous 18F-FES uptake in breast cancer: Nienhuis and colleagues analyze 18F-fluoroestradiol PET to assess estrogen receptor expression heterogeneity in tumor and normal tissue at multiple sites in patients with metastatic breast cancer.
Page 1212
89Zr-anti-CD20 mAb theranostics: Yoon and colleagues use PET/CT to assess tumor targeting with 2 89Zr-labeled anti-CD20 monoclonal antibodies and determine their biodistributions in a preclinical mouse model with CD20 xenografts.
Page 1219
PARP-1 radiotherapy in glioblastoma: Jannetti and colleagues demonstrate in mouse studies the potential for 131I- poly(ADP-ribose) polymerase 1 therapeutics to induce DNA damage and apoptosis in cancer cells while sparing healthy brain tissue.
Page 1225
Anti–Müllerian-inhibiting substance receptor type II antibody: Deshayes and colleagues assess in preclinical models the possibility of using the radiolabeled 16F12 mouse monoclonal antibody in a theranostic approach for small-volume ovarian peritoneal carcinomatosis, such as after cytoreductive surgery.
Page 1234
Measuring BAT activity with radiometry: Crandall and colleagues evaluate in healthy human subjects the operating characteristics of a microwave radiometry system in noninvasive assessment of activated and nonactivated brown adipose tissue to reflect metabolic activity.
Page 1243
β-cell mass imaging with 11C-(+)-PHNO: Bini and colleagues evaluate PET brain radioligands in the pancreas in healthy controls and type-1 diabetes mellitus subjects and identify this D3-preferring receptor agonist as a potential marker of β-cell mass.
Page 1249
PE in sickle cell disease: Tivnan and colleagues explore the influence of chest radiography in patient selection and diagnostic performance of CT pulmonary angiography or ventilation–perfusion scintigraphy in suspected pulmonary emboli in sickle cell disease.
Page 1255
18F-GE180 versus 11C-PBR28: Zanotti-Fregonara and colleagues compare 18F-GE180, a third-generation PET tracer for quantifying the translocator protein (TSPO), and the well-established TSPO tracer 11C-PBR28 by scanning with each tracer during the same day in the same subjects.
Page 1260
Quantification of 18F-PBR111 binding: Ottoy and colleagues determine whether the test–retest variability of 18F-PBR111, a second-generation PET ligand that specifically binds to the translocator protein, is acceptable to detect a psychosis-associated neuroinflammatory signal in schizophrenia.
Page 1267
Dosimetry of 18F-FE-PE2I: Lizana and colleagues investigate the whole-body biodistribution and dosimetry of this radioligand in healthy volunteers to determine its utility as a suitable PET imaging agent for the dopamine transporter.
Page 1275
Dosimetry with updated ICRP phantoms: Josefsson and colleagues use 68Ga-DOTATATE PET/CT scans to compare dosimetry based on the most recent International Commission on Radiological Protection standards (phantoms and tissue-weighting factors) with dosimetry based on prior standards.
Page 1281
Body-surface-area model limitations: Kafrouni and colleagues quantitatively assess the ability of the body-surface-area model to predict tumor-absorbed dose and treatment outcome with 90Y microspheres through retrospective voxel-based dosimetry.
Page 1289
Comparing multimeric 68Ga-RGD peptides: Lobeek and colleagues compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate–based tracers in an αvβ3 integrin–expressing tumor model and a model in which αvβ3 integrin is expressed solely on the neovasculature.
Page 1296
18F-FDG PET in the octopus: Zullo and colleagues report on a method of administering 18F-FDG to the common octopus to perform a PET biodistribution assay characterizing glucose metabolism in organs and regenerating tissues.
Page 1302
Imaging liver injury with 18F-DFA PET: Salas and colleagues evaluate in a preclinical model whether 18F-2-deoxy-2-fluoroarabinose, a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure.
Page 1308
Fluorescence imaging of rucaparib: Kossatz and colleagues describe the intrinsic fluorescence properties of the clinically approved poly(ADP-ribose)polymerase inhibitor rucaparib and its potential to directly measure drug distribution and target engagement.
Page 1316
Harmonization for multicenter PET studies: Orlhac and colleagues propose a method that, by removing the center effect while preserving patient-specific effects, standardizes features measured from PET images obtained using different imaging protocols.
Page 1321
PET/MR measurement of CBF: Ssali and colleagues detail a noninvasive PET/MR imaging approach to cerebral blood flow quantification in 15O-water PET that eliminates the need to measure arterial input function.
Page 1329
- © 2018 by the Society of Nuclear Medicine and Molecular Imaging.